Mixed Earnings Outlook For Top Korean Pharma Firms
This article was originally published in PharmAsia News
Executive Summary
Major South Korean pharma firms are likely to post higher sales in the calendar first quarter driven by brisk exports, but mixed operating profits amid few signs of a recovery in the domestic prescription market. Increased spending for R&D stemming from the industry’s push to develop new drugs is also damping companies’ bottom lines, according to securities firms.